BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34476650)

  • 41. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.
    Terashima T; Morizane C; Ushiama M; Shiba S; Takahashi H; Ikeda M; Mizuno N; Tsuji K; Yasui K; Azemoto N; Satake H; Nomura S; Yachida S; Sugano K; Furuse J
    Jpn J Clin Oncol; 2022 Oct; 52(10):1105-1114. PubMed ID: 36135357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
    Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK
    Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Familial pancreatic cancer].
    Zalatnai A
    Magy Onkol; 2006; 50(2):163-8. PubMed ID: 16888680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
    Shindo K; Yu J; Suenaga M; Fesharakizadeh S; Cho C; Macgregor-Das A; Siddiqui A; Witmer PD; Tamura K; Song TJ; Navarro Almario JA; Brant A; Borges M; Ford M; Barkley T; He J; Weiss MJ; Wolfgang CL; Roberts NJ; Hruban RH; Klein AP; Goggins M
    J Clin Oncol; 2017 Oct; 35(30):3382-3390. PubMed ID: 28767289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.
    Goehringer C; Sutter C; Kloor M; Gebert J; Slater EP; Keller M; Treiber I; Ganschow P; Kadmon M; Moog U
    Fam Cancer; 2017 Apr; 16(2):303-309. PubMed ID: 27838800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
    Kimura H; Klein AP; Hruban RH; Roberts NJ
    Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new targeted treatment for patients with a germline
    Verdaguer H; Acosta D; Macarulla T
    Future Oncol; 2020 Nov; 16(33):2691-2700. PubMed ID: 32799562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Sorscher S; Ansley K; Delaney SD; Ramkissoon S
    Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients.
    Baz M; Gondran-Teiller V; Bressac B; Cabaret O; Fievet A; Dimaria M; Goldbarg V; Colas C; Bonnet-Dupeyron MN; Tinat J; Lebrun M; Mari V; Limacher JM; Corsini C; Ginglinger E; Saurin JC; Brahimi A; Rouzier C; Giraud S; Schuster H; Hollebecque A; Boige V; Cauchin E; Malka D; Caron O; Rouleau E
    Dig Dis Sci; 2023 Apr; 68(4):1525-1528. PubMed ID: 36315333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes.
    Hu C; LaDuca H; Shimelis H; Polley EC; Lilyquist J; Hart SN; Na J; Thomas A; Lee KY; Davis BT; Black MH; Pesaran T; Goldgar DE; Dolinsky JS; Couch FJ
    JCO Precis Oncol; 2018; 2():. PubMed ID: 31497750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
    Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
    Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of novel germline mutations for breast cancer in non-BRCA1/2 families.
    Aloraifi F; McDevitt T; Martiniano R; McGreevy J; McLaughlin R; Egan CM; Cody N; Meany M; Kenny E; Green AJ; Bradley DG; Geraghty JG; Bracken AP
    FEBS J; 2015 Sep; 282(17):3424-37. PubMed ID: 26094658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
    Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
    Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.